In addition, CA-MSCs derived from cervical cancer patients were also shown to prevent antigen-specific CD8+ T lymphocytes from destroying CaSki cells in vitro, a human cervical cancer cell line (106). The gene discussed is CD8A; the disease is cervical cancer.